PMID- 35762036
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20221207
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 88
IP  - 10
DP  - 2022 Oct
TI  - Rapid review and meta-analysis of adverse events associated with molnupiravir in 
      patients with COVID-19.
PG  - 4403-4411
LID - 10.1111/bcp.15449 [doi]
AB  - AIMS: The aim of this study was to evaluate the safety profile of molnupiravir in 
      COVID-19 patients. METHODS: PubMed, Cochrane Library, medRxive and Google Scholar 
      were searched for articles published up to April 25, 2022. Meta-analysis was 
      performed using Comprehensive Meta-Analysis software. RESULTS: Four trials 
      involving 2241 patients met the inclusion criteria. No significant difference was 
      observed between molnupiravir at 200, 400 and 800 mg compared with placebo 
      (200 mg: risk ratio [RR] = 0.97; 95% confidence interval [CI]: 0.78-1.20; 
      P = .80; 400 mg: RR = 0.81; 95% CI: 0.64-1.02; P = .07; 800 mg: RR = 0.94; 95% 
      CI: 0.83-1.06; P = .36) for any adverse events (AEs); at 200, 400 and 800 mg 
      compared with placebo (200 mg: RR = 0.81; 95% CI: 0.41-1.63; P = .57; 400 mg: 
      RR = 0.82; 95% CI: 0.41-1.61; P = .56; 800 mg: RR = 0.80; 95% CI: 0.59-1.08; 
      P = .15) for serious adverse events; at 200, 400 and 800 mg compared with placebo 
      (200 mg: RR = 1.74; 95% CI: 0.48-6.30; P = .39; 400 mg: RR = 1.07; 95% CI: 
      0.28-4.09; P = .91; 800 mg: RR = 0.47; 95% CI: 0.17-1.28; P = .14) for AEs 
      leading to death; and at 200, 400 and 800 mg compared with placebo (200 mg: 
      RR = 1.50; 95% CI: 0.26-8.55; P = .64; 400 mg: RR = 0.99; 95% CI: 0.17-5.68; 
      P = .99; 800 mg: RR = 0.61; 95% CI: 0.31-1.23; P = .17) for treatment 
      discontinuation due to AEs. CONCLUSION: This meta-analysis showed that the use of 
      three doses of molnupiravir (200, 400 and 800 mg) is safe for COVID-19 patients. 
      Further research is needed to confirm the present findings.
CI  - (c) 2022 British Pharmacological Society.
FAU - Amani, Behnam
AU  - Amani B
AUID- ORCID: 0000-0003-4298-1807
AD  - Department of Health Management and Economics, School of Public Health, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Zareei, Sara
AU  - Zareei S
AUID- ORCID: 0000-0002-5206-3105
AD  - Department of Cell and Molecular Biology, Faculty of Biological Sciences, 
      Kharazmi University, Tehran, Iran.
FAU - Amani, Bahman
AU  - Amani B
AUID- ORCID: 0000-0002-2340-189X
AD  - Department of Health Management and Economics, School of Public Health, Tehran 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20220711
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Hydroxylamines)
RN  - 5CSZ8459RP (Cytidine)
RN  - YA84KI1VEW (molnupiravir)
SB  - IM
MH  - Cytidine/analogs & derivatives
MH  - Humans
MH  - Hydroxylamines
MH  - *COVID-19 Drug Treatment
PMC - PMC9349444
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - molnupiravir
OT  - safety
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/06/29 06:00
MHDA- 2022/09/14 06:00
PMCR- 2022/07/11
CRDT- 2022/06/28 02:13
PHST- 2022/05/28 00:00 [revised]
PHST- 2022/03/16 00:00 [received]
PHST- 2022/06/06 00:00 [accepted]
PHST- 2022/06/29 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PHST- 2022/06/28 02:13 [entrez]
PHST- 2022/07/11 00:00 [pmc-release]
AID - BCP15449 [pii]
AID - 10.1111/bcp.15449 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2022 Oct;88(10):4403-4411. doi: 10.1111/bcp.15449. Epub 2022 
      Jul 11.